

Supplemental tables

Table S1. Cost of healthcare personnel, laboratory test fees, HCV medications, adverse events consumables, hospitalizations, and emergency room visits

Category	Consumable/Event	Cost
Health-care personnel , imaging, and laboratory test fees	Complete blood count with platelet count and differential (CPT ^a code: 85025)	\$11
	HCV RNA quantification (CPT code: 87522)	\$50
	Liver transplant monitor (CPT code:80053)	\$15
	Abdominal ultrasound (CPT code: 76700)	\$109
	Abdominal CT with contrast (or MRI depending on renal function) (CPT code: 74160)	\$360
	Hepatologist visit (CPT code: 99204/99205)	Initial: \$191 Subsequent: \$113
	Nurse visit (CPT code:99211)	\$21
HCV medications	Telaprevir	\$4,606 per week
	Pegylated-interferon	\$633 per week
	Ribavirin	\$103 per week
Adverse event management consumables	Erythropoietin- α	\$525 per 40,000 IU ^b dose
	Filgrastim	\$132 per 150 mcg dose (Neupogen); \$3,758 per 6mg/0.6mL dose (Neulasta)
	Eltrombopag	\$156 per 50 mg dose
	Blood transfusions	\$210 per unit

Hospitalizations	Anemia (ICD9 ^c : 285.9)	\$4,590
	Cellulitis (ICD9: 682.9)	\$3,999
	Urinary Tract Infection (ICD9: 599.0)	\$5,370
	Renal Insufficiency (ICD9:584.9)	\$7,002
	Toxic Diffuse Goiter (ICD9: 242.00)	\$6,307
	Chest Pain (ICD9: 786.50)	\$4,679
Emergency room	Anemia (ICD9: 285.9)	\$494
	Infection (ICD9:592.0)	\$1,181
	Syncope (ICD9: 780.2)	\$600
	Renal Insufficiency (ICD9: 584.9)	\$365
	Chest Pain (ICD9: 786.50)	\$690
	Weakness (ICD9: 728.87)	\$553
	Fever (ICD9: 276.8)	\$508
	Abdominal Pain (ICD9: 553.2)	\$422
	Severe Rash (ICD9:782.1)	\$122

^a CPT: Current procedural terminology

^b IU: International units

^c ICD-9: International classification of disease

Table S2. Comparison of SVR rates in various subgroups

Category	Sustained virologic response rate (%)	p-value
Completed treatment	72	<0.01
Discontinued due to adverse events	38	
Completed 48 weeks	75	0.33
Completed RGT	60	
Black	21	<0.01
White	50	
Males	44	0.93
Females	45	
Previous treatment response		0.24
Naïve	48	
Relapsers	55	
Non-responders	41	
Intolerance	20	
HIV/HCV co-infected	56	0.31
HCV mono-infection	43	
Fib-4 score ≥ 3.25	36	0.06
Fib-4 score < 3.25	49	

Table S3. Cost of medications and blood transfusions for adverse event management

	Patients Receiving n (%)	Median Doses/Units Per Treatment (IQR)	Median Cost Per Treatment (IQR)	Total cost
Epoetin-α	71 (48%)	15 (IQR:6-30) (Range: 1-43)	\$7,875 (\$3,150 – \$13,708)	\$701,893
G-CSF	14 (8%)	14 (2-29) (Range: 1-46)	\$1,851 (\$265 – \$3,758)	\$32,704
Transfusion	13 (9%)	2 (2-4) (Range: 1-20)	\$421 (\$421 - \$842)	\$13,066

Table S4. Cost of emergency room visits by cause

	ICD-9 code	Number of people	Number of emergency room visits	Total cost
Anemia	285.9	4	5	\$2,472
Infection	592.0	3	4	\$1,917
Syncope	780.2	2	3	\$1,800
Renal insufficiency	584.9	1	2	\$730
Chest pain	786.5	1	1	\$690
Weakness	728.87	1	1	\$553
Fever	276.8	1	1	\$508
Abdominal pain	553.2	1	1	\$422
Severe rash	782.1	1	1	\$122
Total	-	15	19	\$9,214

Table S5. Cost of hospitalizations by cause

	ICD-9 code	Number of people	Number of hospitalizations	Total cost
Anemia	285.9	12	13	\$59,670
Infection	592.0	2	2	\$14,738
Renal insufficiency	584.9	2	2	\$14,004
Toxic diffuse goiter	242.0	1	1	\$6,307
Chest pain	786.5	1	1	\$4,776
Abnormal glucose	790.29	1	1	\$3,003
Total	-	19	20	\$102,403

Table S6. Cost of new direct-acting antivirals and projected cost per SVR

DAA regimen	Cost of medications	Observed SVR rate	Cost per SVR
Simeprevir-based triple therapy (24 weeks)	\$84,024	88%	\$95,482
Simeprevir-based triple therapy (48 weeks)	\$101,688	80%	\$127,110
Sofosbuvir-based triple therapy (12 weeks)	\$92,832	90%	\$103,147
Sofosbuvir and ribavirin (24 weeks)	\$170,472	76%	\$224,305
Simeprevir, sofosbuvir, and ribavirin (12 weeks)	\$155,270	96%	\$161,740